Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.
You may also be interested in...
Bristol Pays Tranzyme $10 Million For Collaboration For Discovery Program
Tranzyme’s first alliance with a Big Pharma should give it a cushion to advance its own pipeline, which includes two Phase II candidates.
Tranzyme Takes On Diabetic Gastroparesis With Novel Ghrelin Agonist
With Phase II efficacy data in hand for the I.V. version of its ghrelin agonist, Tranzyme Pharma has launched a Phase II safety and efficacy study of an oral outpatient formulation in patients with diabetic gastroparesis
Tranzyme Takes On Diabetic Gastroparesis With Novel Ghrelin Agonist
With Phase II efficacy data in hand for the I.V. version of its ghrelin agonist, Tranzyme Pharma has launched a Phase II safety and efficacy study of an oral outpatient formulation in patients with diabetic gastroparesis